Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy
Autore:
Cheung, KL; Evans, AJ; Robertson, JFR;
Indirizzi:
City Hosp Nottingham, Professorial Surg Unit, Dept Surg, Nottingham NG5 1PB, England City Hosp Nottingham Nottingham England NG5 1PB tingham NG5 1PB, England City Hosp Nottingham, Dept Radiol, Nottingham NG5 1PB, England City Hosp Nottingham Nottingham England NG5 1PB tingham NG5 1PB, England
Titolo Testata:
BREAST CANCER RESEARCH AND TREATMENT
fascicolo: 3, volume: 67, anno: 2001,
pagine: 273 - 278
SICI:
0167-6806(200106)67:3<273:TUOBTM>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBJECTIVE MEASUREMENT;
Keywords:
metastatic breast cancer; monitoring; tumour marker; unassessable;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Cheung, KL City Hosp Nottingham, Professorial Surg Unit, Dept Surg, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Nottingham Hucknall Rd Nottingham England NG5 1PB nd
Citazione:
K.L. Cheung et al., "The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy", BREAST CANC, 67(3), 2001, pp. 273-278

Abstract

The role of blood tumour markers is established in the monitoring of response to systemic therapy for patients with metastatic breast cancer assessable by UICC criteria. This paper examines the use of marker measurements (inthe form of a previously devised biochemical index score comprising CA15.3, CEA and ESR) in patients with metastatic lesions unassessable for response by UICC criteria. Of 218 patients with metastatic breast cancer treated over a 2-year period in the Nottingham Breast Unit, 43 patients (20%) had unassessable disease and 36 of them with blood marker results available were studied. Eighty-six per cent of patients were biochemically assessable. Allpatients who achieved biochemical response remained unassessable by UICC criteria. Twenty-two patients progressed initially or subsequently (after aninitial biochemical response), either biochemically or by UICC criteria. Biochemical assessment completely paralleled UICC assessment in all eight patients who progressed by both assessments. Biochemical progression occurredahead of UICC assessment in four of them with a median lead-time of 4.5 months. Biochemical assessment by blood tumour markers is useful in patients with metastatic breast cancer unassessable for response to systemic therapy. These findings need to be confirmed in a larger patient series.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 00:15:13